ClinicalTrials.gg

Program

teclistamab

Also written as “Teclistamab”, “Teclistamab (IV)” and “Teclistamab(SC)”.

Its studies are mostly in Multiple Myeloma · Hematologic Neoplasms, led by Johnson & Johnson.

Furthest: phase 4, since Jun 12, 202511 company-led studies, 10 open or runningNext primary completion: Feb 12, 2027 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Johnson & Johnson1110 open or runningphase 4since Jun 12, 2025Apr 28, 2017Feb 12, 2027phase 4 · NCT07030517

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 28, 2017First study: phase 1 study in Hematologic NeoplasmsFirst studyNCT03145181 · 302 enrolled · United States, France, Netherlands and more
  2. Sep 17, 2020Phase 2 study in Hematologic NeoplasmsNCT04557098 · 194 enrolled · United States, Belgium, Canada and more
  3. Oct 12, 2020Phase 2 study in Multiple MyelomaNCT04586426 · 228 enrolled · United States, Australia, Canada and more
  4. Jan 5, 2021Phase 2 study in Hematologic NeoplasmsNCT04696809 · 40 enrolled · Japan
  5. Oct 8, 2021Phase 3 study in Multiple MyelomaNCT05083169 · 587 enrolled · United States, Argentina, Belgium and more
  6. Mar 31, 2022Phase 1 study in Relapsed/ Refractory Multiple MyelomaNCT05338775 · 74 enrolled · United States, France, Germany and more
  7. Sep 21, 2022Phase 3 study in Multiple MyelomaNCT05552222 · 1,590 planned · United States, Australia, Austria and more
  8. Oct 5, 2022Phase 3 study in Multiple MyelomaNCT05572515 · 614 enrolled · United States, Australia, Austria and more
  9. Jan 5, 2024Phase 3 study in Multiple MyelomaNCT06208150 · 838 enrolled · United States, Argentina, Australia and more
  10. May 17, 2024Phase 1 study in Multiple MyelomaNCT06425991 · 108 enrolled · United States, Australia, Canada and more
  11. Jun 12, 2025Phase 4 study in Multiple MyelomaNCT07030517 · 75 enrolled · India
  12. Nov 3, 2026Primary completion moved from 2026-11-03 to 2027-02-12Date moved laterphase 4 · +3 months · NCT07030517

Ahead

  1. Feb 12, 2027Primary completion: phase 4 study in Multiple MyelomaNCT07030517
  2. Apr 30, 2031Primary completion: phase 3 study in Multiple MyelomaNCT05552222

TargetBeta

“A bispecific humanized monoclonal antibody against human CD3, a T-cell surface antigen, and human B-cell maturation antigen (BCMA; TNFRSF17), a tumor-associated antigen (TAA) expressed on plasma cells, ”NCIt, by rule
“T cell surface glycoprotein CD3 binding agent; Tumor necrosis factor receptor superfamily member 17 binding agent”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
elranatamabrulePfizerphase 415
linvoseltamabruleRegeneron Pharmaceuticalsphase 413
etentamigAbbViephase 311
ramantamigJohnson & Johnsonphase 37
Anti-CD3/Anti-BCMA Bispecific Antibody TQB2934Sino Biopharmaceuticalphase 34
GPRC5D/BCMA/CD3-targeting T-cell Engager IBI3003ruleInnovent Biologicsphase 34
cizutamigruleUCBphase 25
vonsetamigruleRegeneron Pharmaceuticalsphase 23
Anti-BCMA/CD38/CD3 Trispecific Antibody ABBV-2001AbbViephase 22
LVV Expressing VSV Glycoprotein/Anti-CD3 scFv Containing Transgene Encoding for Anti-BCMA CAR KLN-1010rulekelonia-therapeutics-incphase 11

Studies

All 11 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07030517Multiple Myeloma · India4Active, not recruitingFeb 12, 202775
NCT06425991Multiple Myeloma · United States, Australia, Canada and more1Active, not recruitingApr 21, 2025108
NCT06208150Multiple Myeloma · United States, Argentina, Australia and more3Active, not recruitingApr 1, 2026838
NCT05572515Multiple Myeloma · United States, Australia, Austria and more3Active, not recruitingOct 13, 2025614
NCT05552222Multiple Myeloma · United States, Australia, Austria and more3RecruitingApr 30, 20311,590
NCT05338775Relapsed/ Refractory Multiple Myeloma · United States, France, Germany and more1Active, not recruitingMay 22, 202574
NCT05083169Multiple Myeloma · United States, Argentina, Belgium and more3Active, not recruitingAug 1, 2025587
NCT04696809Hematologic Neoplasms · Japan2CompletedApr 13, 202640
NCT04586426Multiple Myeloma · United States, Australia, Canada and more2Active, not recruitingMar 18, 2025228
NCT04557098Hematologic Neoplasms · United States, Belgium, Canada and more2Active, not recruitingNov 9, 2021194
NCT03145181Hematologic Neoplasms · United States, France, Netherlands and more1Active, not recruitingSep 25, 2025302

How it is read

Names in the registry

  • “Teclistamab”, 10 entries
  • “Teclistamab (IV)”, 1 entry
  • “Teclistamab(SC)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.